ArticleJournal of thoracic disease2017

Osimertinib for advanced non-small cell lung cancer harboring EGFR mutation exon 20 T790M, acquired resistant mutation for first- or second-generation EGFR-TKI.

Yusuke Okuma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.